comparemela.com
Home
Live Updates
Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium : comparemela.com
Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer
Related Keywords
United States
,
Spain
,
Barcelona
,
Comunidad Autonoma De Cataluna
,
Olipriya Das
,
Alanh Auerbach
,
Alejandro Mart
,
Exchange Commission
,
Puma Biotechnology Inc
,
European Commission
,
Drug Administration
,
Nasdaq
,
Head Of Medical Oncology Service
,
Puma Biotechnology
,
Cancer Therapeutics Symposium
,
Medical Oncology Service
,
Hospital Quir
,
Puma Patient Lynx
,
Fetal Toxicity
,
Full Prescribing Information
,
Annual Report
,
Mariann Ohanesian
,
Russo Partners
,
Puma
,
Biotechnology
,
Presents
,
Pdated
,
Findings
,
Rom
,
Hase
,
Summit
,
Basket
,
Trial
,
Neratinib
,
Egfr
,
Exon
,
Mutant
,
Nsclc
,
022
,
Hortc
,
Racr
,
Symposium
,
comparemela.com © 2020. All Rights Reserved.